A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study
Amantadine has begun to be used as a possible alternative in COVID-19 therapy to mitigate its effects. There is anecdotal evidence that patients with Parkinson's disease (PD) treated with amantadine and who test positive for COVID-19 often do not develop clinical manifestations of COVID-19.Obje...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2022-12-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/1919 |
| _version_ | 1797876298323853312 |
|---|---|
| author | Z. A. Zalyalova S. E. Munasipova D. M. Khasanova G. R. Ilyina Z. G. Khayatova N. I. Bagdanova |
| author_facet | Z. A. Zalyalova S. E. Munasipova D. M. Khasanova G. R. Ilyina Z. G. Khayatova N. I. Bagdanova |
| author_sort | Z. A. Zalyalova |
| collection | DOAJ |
| description | Amantadine has begun to be used as a possible alternative in COVID-19 therapy to mitigate its effects. There is anecdotal evidence that patients with Parkinson's disease (PD) treated with amantadine and who test positive for COVID-19 often do not develop clinical manifestations of COVID-19.Objective: to compare the clinical course of COVID-19 in patients with PD who took or did not take amantadine sulfate.Patients and methods. A prospective continuous study included 142 patients with PD who were treated in Republican Clinical Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy in Kazan from October 2021 to January 2022. Patients filled out a proprietary internally developed questionnaire.Results and discussion. Out of 142 individuals with PD COVID-19 occurred in 77 (54.2%), of which 52.0% had a mild course, 39.0% had a moderate course, 2.6% had a severe course, and in 6.5% the severity of the disease has not been established. Deterioration after COVID-19 infection was noted by 36% of patients: the appearance or increase in motor fluctuations (41%), increased tremor, stiffness or slowness (31%), the appearance of "exhaustion" of the effect of a single dose of levodopa (13%), the appearance or increased dyskinesia (21%), hallucinations (3.5%). Patients taking amantadine sulfate had PD much longer (11.5±5.62 years versus 5.12±3.24 years) and had a more pronounced (III–IV) stage of the disease. These patients were more likely to experience mild COVID-19 (in 60.87% of cases), in contrast to patients not receiving amantadine sulfate (only in 48.15% of cases). There was no correlation between the severity of COVID-19 and levodopa intake.Conclusion. The results of the study showed that patients with PD taking amantadine sulfate are more likely to have a mild course of COVID-19. |
| first_indexed | 2024-04-10T02:01:04Z |
| format | Article |
| id | doaj.art-90b9f6cee96d4cf1afe6c53e6c9a4c59 |
| institution | Directory Open Access Journal |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| last_indexed | 2024-04-10T02:01:04Z |
| publishDate | 2022-12-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj.art-90b9f6cee96d4cf1afe6c53e6c9a4c592023-03-13T08:42:22ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422022-12-01146404810.14412/2074-2711-2022-6-40-481321A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative studyZ. A. Zalyalova0S. E. Munasipova1D. M. Khasanova2G. R. Ilyina3Z. G. Khayatova4N. I. Bagdanova5Kazan State Medical University, Ministry of Health of Russia; Republican Clinical Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy, Ministry of Health of the Republic of Tatarstan; Hospital for War Veterans; Clinical Hospital “Railway Medicine“Kazan State Medical University, Ministry of Health of Russia; Republican Clinical Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy, Ministry of Health of the Republic of Tatarstan; Hospital for War VeteransRepublican Clinical Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy, Ministry of Health of the Republic of Tatarstan; Hospital for War VeteransRepublican Clinical Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy, Ministry of Health of the Republic of Tatarstan; Hospital for War VeteransClinical Hospital “Railway Medicine“Republican Clinical Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy, Ministry of Health of the Republic of Tatarstan; Hospital for War VeteransAmantadine has begun to be used as a possible alternative in COVID-19 therapy to mitigate its effects. There is anecdotal evidence that patients with Parkinson's disease (PD) treated with amantadine and who test positive for COVID-19 often do not develop clinical manifestations of COVID-19.Objective: to compare the clinical course of COVID-19 in patients with PD who took or did not take amantadine sulfate.Patients and methods. A prospective continuous study included 142 patients with PD who were treated in Republican Clinical Diagnostic Center for Extrapyramidal Pathology and Botulinum Therapy in Kazan from October 2021 to January 2022. Patients filled out a proprietary internally developed questionnaire.Results and discussion. Out of 142 individuals with PD COVID-19 occurred in 77 (54.2%), of which 52.0% had a mild course, 39.0% had a moderate course, 2.6% had a severe course, and in 6.5% the severity of the disease has not been established. Deterioration after COVID-19 infection was noted by 36% of patients: the appearance or increase in motor fluctuations (41%), increased tremor, stiffness or slowness (31%), the appearance of "exhaustion" of the effect of a single dose of levodopa (13%), the appearance or increased dyskinesia (21%), hallucinations (3.5%). Patients taking amantadine sulfate had PD much longer (11.5±5.62 years versus 5.12±3.24 years) and had a more pronounced (III–IV) stage of the disease. These patients were more likely to experience mild COVID-19 (in 60.87% of cases), in contrast to patients not receiving amantadine sulfate (only in 48.15% of cases). There was no correlation between the severity of COVID-19 and levodopa intake.Conclusion. The results of the study showed that patients with PD taking amantadine sulfate are more likely to have a mild course of COVID-19.https://nnp.ima-press.net/nnp/article/view/1919parkinson's diseasecovid-19new coronavirus infectionamantadine sulfatelevodopaα-synucleinpneumonia |
| spellingShingle | Z. A. Zalyalova S. E. Munasipova D. M. Khasanova G. R. Ilyina Z. G. Khayatova N. I. Bagdanova A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study Неврология, нейропсихиатрия, психосоматика parkinson's disease covid-19 new coronavirus infection amantadine sulfate levodopa α-synuclein pneumonia |
| title | A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study |
| title_full | A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study |
| title_fullStr | A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study |
| title_full_unstemmed | A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study |
| title_short | A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study |
| title_sort | new role of amantadines in covid 19 in patients with parkinson s disease results of own comparative study |
| topic | parkinson's disease covid-19 new coronavirus infection amantadine sulfate levodopa α-synuclein pneumonia |
| url | https://nnp.ima-press.net/nnp/article/view/1919 |
| work_keys_str_mv | AT zazalyalova anewroleofamantadinesincovid19inpatientswithparkinsonsdiseaseresultsofowncomparativestudy AT semunasipova anewroleofamantadinesincovid19inpatientswithparkinsonsdiseaseresultsofowncomparativestudy AT dmkhasanova anewroleofamantadinesincovid19inpatientswithparkinsonsdiseaseresultsofowncomparativestudy AT grilyina anewroleofamantadinesincovid19inpatientswithparkinsonsdiseaseresultsofowncomparativestudy AT zgkhayatova anewroleofamantadinesincovid19inpatientswithparkinsonsdiseaseresultsofowncomparativestudy AT nibagdanova anewroleofamantadinesincovid19inpatientswithparkinsonsdiseaseresultsofowncomparativestudy AT zazalyalova newroleofamantadinesincovid19inpatientswithparkinsonsdiseaseresultsofowncomparativestudy AT semunasipova newroleofamantadinesincovid19inpatientswithparkinsonsdiseaseresultsofowncomparativestudy AT dmkhasanova newroleofamantadinesincovid19inpatientswithparkinsonsdiseaseresultsofowncomparativestudy AT grilyina newroleofamantadinesincovid19inpatientswithparkinsonsdiseaseresultsofowncomparativestudy AT zgkhayatova newroleofamantadinesincovid19inpatientswithparkinsonsdiseaseresultsofowncomparativestudy AT nibagdanova newroleofamantadinesincovid19inpatientswithparkinsonsdiseaseresultsofowncomparativestudy |